Does microdosing psilocybin help with depression?

Nobody knows, because it has never been tested in people with depression. Survey and naturalistic studies show that people who microdose report lower depression scores — Rootman et al. (2021) surveyed 4,050 microdosers and 4,653 non-microdosers and found lower depression, anxiety and stress among microdosers who reported mental health concerns. But the placebo-controlled trials, all conducted in healthy volunteers, found no mood benefit over placebo: Szigeti et al. (2021, n=191) found the microdose and placebo groups improved equally, and Cavanna et al. (2022, n=34) found no effect on any measure. No placebo-controlled trial has enrolled a clinically depressed population, which Polito and Liknaitzky (2024) identify as a central gap in the literature.

What does the research say about microdosing for depression?

The answer depends on study design. Observational studies with large samples show consistent associations between microdosing and lower depression scores. Controlled trials — roughly 19 of them as of Polito and Liknaitzky's 2024 count — have generally found no benefit over placebo on mood and well-being outcomes, though one pooled analysis of three trials did find improved divergent thinking. An early systematic review by Ona and colleagues (2020) in Neuroscience and Biobehavioral Reviews found highly contradictory results across the literature, documenting both benefits and detriments and calling for more rigorous methods.

Why do people say microdosing helped their depression if the research is mixed?

Expectancy is a powerful and real psychological mechanism. Kaertner and colleagues (2021) surveyed 81 people before, during and after a four-week microdosing regimen and found that positive expectations measured at baseline predicted how much their well-being subsequently improved — which the authors interpreted as evidence of a significant placebo response. Note that Kaertner's study had no placebo arm and no random assignment, so it cannot establish that expectancy mattered more than the drug. Szigeti and colleagues (2023) later modelled this formally, showing that imperfect blinding combined with positive expectancy produces activated expectancy bias that can manufacture false positive findings. The experiences people report are real. What is uncertain is whether psilocybin's pharmacology or the belief that it will work is the primary driver.

How is microdosing different from full-dose psilocybin therapy for depression?

Full-dose psilocybin therapy uses doses high enough to produce a pronounced altered state, typically 20-30 mg of pure psilocybin, administered in a clinical setting with trained facilitators. It has a substantially stronger evidence base, including multiple randomized controlled trials in diagnosed patients showing significant antidepressant effects. Microdosing uses sub-perceptual doses — across the controlled literature, 0.1-0.5 g of dried mushrooms — taken on a repeating schedule without producing a noticeable psychedelic experience. The controlled evidence for full-dose therapy in depression is robust; for microdosing in depression it is entirely absent.

What is the placebo problem with microdosing research?

Psilocybin is psychoactive even at microdoses, so participants often notice subtle effects that let them guess whether they received the active substance. When they guess correctly, their expectation of improvement rises, and that expectation produces real improvements in self-reported mood — which the trial then records as a drug effect. Szigeti's 2021 self-blinding study (n=191) showed the pattern directly: the small acute differences favouring psilocybin were explainable by participants breaking blind. The 2023 follow-up formalised it as activated expectancy bias and introduced the Correct Guess Rate Curve to estimate what a genuinely blinded trial would have found.

Is there any controlled evidence that microdosing treats depression?

No. No completed placebo-controlled trial has targeted depression as a clinical condition using a psilocybin microdosing protocol. The controlled trials that exist tested broader outcomes — well-being, mood, creativity, cognition — in healthy volunteers, and generally found no significant benefit over placebo. Polito and Liknaitzky (2024) list the exclusive use of non-clinical populations as one of eight reasons the current literature cannot determine whether microdosing works. Observational studies show associations between microdosing and lower depression scores, but those designs cannot establish causation.

Does microdosing have any downsides the research has picked up?

Yes, and it is the most consistent finding in the controlled literature. Pinhas and colleagues' 2026 preregistered meta-analysis pooled 14 studies (N=1,614) and 59 effect sizes and found one statistically reliable effect across all cognitive domains: a significant decrease in cognitive control. This was not moderated by substance, dose, duration, or whether testing happened on or off the drug. It converges with Cavanna's 2022 trial, which found no benefits but did detect a few small changes in the direction of cognitive impairment. Ona's 2020 review had already noted that the literature documents detriments as well as benefits.

Microdosing Psilocybin for Depression: Research vs Anecdote

Psilocybin Microdosing

953 participants

Rootman's 2021 naturalistic study found 953 microdosers reported significantly lower depression, anxiety, and stress than 180 non-microdosing adults. Yet two subsequent placebo-controlled trials found zero improvement in well-being once expectations were accounted for.

Rootman et al. (incl. Stamets), Scientific Reports, 2021

participants in Cavanna's 2022 double-blind trial; no improvement in well-being vs. placebo

191

participants in Szigeti's 2021 self-blinding study; benefits disappeared when expectancy was modeled

Baseline hope

was the strongest predictor of outcomes in Kaertner's 2021 study, not the psilocybin dose

Rootman et al. (incl. Stamets), Scientific Reports, 2021

View as image ↗

The gap between what people report microdosing did for their depression and what controlled trials have confirmed is one of the most interesting puzzles in psychedelic science. It is not a simple story of hype versus reality. It is a genuine scientific tension with a specific, documented explanation. That explanation is more illuminating than either believers or skeptics usually acknowledge.

The short answer to whether microdosing psilocybin helps with depression is this: people who microdose consistently report lower depression in surveys and observational studies, but when researchers add a placebo control and account for participants' expectations, the measurable benefit disappears. The largest naturalistic study in the field tracked 953 people and found real, significant differences on validated scales. Two placebo-controlled trials then found no effect. A 2021 study identified why: baseline expectations, not psilocybin, predicted who got better.

This article is part of the broader guide on what microdosing psilocybin is and what the research says.

Key Takeaways

Rootman's 2021 cross-sectional survey of 953 microdosers found significantly lower depression, anxiety, and stress scores versus 180 non-microdosing comparators on validated scales
A 30-day prospective follow-up of the same cohort showed small-to-medium improvements in mood and mental health over time (Rootman et al., 2022)
Cavanna's 2022 double-blind trial (n=34) found zero improvement in well-being after psilocybin microdosing versus placebo, even though participants correctly guessed which condition they were in
Szigeti's 2021 self-blinding study (n=191) found initial improvements in well-being and mindfulness that fully disappeared once researchers statistically controlled for expectancy
Kaertner's 2021 study (Carhart-Harris lab) found that positive baseline expectations were the strongest predictor of mental health improvements, more than the psilocybin itself
Raval's 2021 pig brain study found that a single psilocybin dose increased synaptic density in the brain, providing a biological rationale for why microdosing could theoretically produce real effects even in the absence of a visible psychedelic experience

The Anecdotal Case for Microdosing Psilocybin and Depression: Compelling but Uncontrolled

Before the studies, there were the forums. Thousands of first-person accounts from people who tried microdosing psilocybin and came back to describe a depression that had lifted when nothing else had. These accounts share common patterns: mood shifted gradually over weeks, not hours; emotional reactivity softened; motivation returned. The people telling these stories are detailed and specific, and most have no obvious incentive to exaggerate.

This is what drove the science. Researchers began studying microdosing systematically because so many people reported benefits that conventional psychiatry wasn't producing.

The first systematic review of the microdosing evidence, published by Ona and colleagues in the International Journal of Neuropsychopharmacology in 2020, looked across the available research and reached an uncomfortable early conclusion: the positive results were real, but they were almost certainly partly driven by expectancy and placebo effects.^[9] Most of the evidence at that time came from unblinded observational studies, where everyone involved knew who was taking psilocybin and who was not. That design makes it structurally impossible to separate a drug's pharmacological effects from the psychological effects of believing you are taking a mind-altering substance.

This is not a flaw unique to microdosing research. It is also harder to solve than most clinical trial challenges. Psilocybin is psychoactive even at low doses, and participants often notice subtle effects that allow them to guess whether they received the active substance. That makes maintaining proper blind conditions difficult and controlling for expectancy effects challenging by design.

Understanding the anecdotal evidence is necessary context for everything that follows. People report real experiences of improvement. What science is trying to establish is whether psilocybin is causing them.

Rootman's 953-Person Study: The Best Naturalistic Evidence Available

If you want to understand why the case for microdosing and depression looks compelling, start with the Rootman 2021 study. Rootman and colleagues, a team that included mycologist Paul Stamets, surveyed 953 adults who were actively microdosing psychedelics and compared them to 180 adults who were not microdosing. All participants completed validated mental health assessments including the DASS-21, a standardized measure of depression, anxiety, and stress widely used in clinical research.^[1]

The microdosers scored significantly lower on every measure. Lower depression. Lower anxiety. Lower stress. The differences were not trivial. Among the subgroup with prior mental health concerns, the differences between microdosers and comparators were even more pronounced.

A year later, Rootman's team published a 30-day prospective follow-up of the same cohort. Participants completed assessments at baseline and again after 30 days of their normal microdosing routine. The microdosers showed small-to-medium improvements in mood, mental health, and psychomotor performance compared to the non-microdosing group over that period. Within-person change was statistically significant. One specific finding worth noting: the Stamets Stack, a combination of psilocybin with lion's mane mushroom and niacin, did not produce additional mood benefit compared to psilocybin alone.^[2]

These two papers represent the most rigorous naturalistic microdosing research conducted to date. They involve a large sample, a comparison group, validated instruments, and longitudinal follow-up. For readers wanting to understand the methodology and what naturalistic studies can and cannot conclude, the dedicated analysis of naturalistic microdosing study results covers this in depth.

The critical caveat is that this is not a randomized controlled trial. Nobody assigned participants to a microdosing condition. The 953 people in the microdosing group were people who chose to microdose. People who choose to microdose are probably more motivated about their mental health, more likely to hold high expectations of benefit, and more likely to make other positive behavioral changes alongside their microdosing practice. The comparison group was also self-selected. None of this is a flaw in Rootman's execution. Running a controlled trial with a Schedule I substance is extraordinarily difficult. But it means these data cannot establish that psilocybin is causing the lower depression scores.

What Happened When Researchers Added a Control Group

The controlled evidence points in a different direction. This is the part most popular accounts of microdosing research leave out.

In 2022, Cavanna and colleagues published the first double-blind placebo-controlled trial of microdosing with whole psilocybin mushrooms. Thirty-four participants received either 0.5g of dried Psilocybe cubensis or an identical-looking placebo, under true blinded conditions, and completed assessments of well-being, creativity, and cognitive function across the trial period.^[3]

The psilocybin group showed no improvement over the placebo group on any measure. Participants who correctly guessed they had received psilocybin did experience more intense effects on dosing days, which confirms the drug was pharmacologically active at the doses used. But those acute effects produced no lasting psychological benefit. Well-being scores between the two groups were statistically indistinguishable at the end of the trial.

This was a small trial. Thirty-four participants cannot rule out a real but modest effect that only larger samples could detect. But it can establish that in this controlled setting, the effects people report in observational studies were absent.

The larger and more methodologically innovative study came from Szigeti and colleagues at Imperial College London, published in eLife in 2021. Szigeti enrolled 191 participants in what became the largest placebo-controlled psychedelic study ever conducted to that point. The design was inventive: participants self-blinded their own microdoses by placing psilocybin or placebo into opaque capsules they had prepared in advance, then completed cognitive and psychological assessments over four weeks.^[4]

The initial results looked familiar. People in the psilocybin group showed improvements in well-being, mindfulness, and problem-solving ability (what researchers call convergent thinking). Then Szigeti's team did something most microdosing researchers had not yet attempted: they statistically modeled each participant's expectancy and their confidence about which condition they were actually in.

Every improvement disappeared. When expectancy was accounted for, there were no reliable differences between the psilocybin and placebo groups on any measure. The improvements were genuine experiences for the people who had them. What they were not, according to this analysis, was caused by the psilocybin.

The full breakdown of the self-blinding study and its methodology explores what the Szigeti design reveals about the placebo problem in psychedelic research.

The Expectancy Explanation: Why What You Believe Predicts What You Feel

The finding that made the divergence between Rootman and Cavanna/Szigeti interpretable came from Kaertner and colleagues, published in Scientific Reports in 2021. The research team, which included Robin Carhart-Harris, measured participants' expectations before they began microdosing: specifically, how much improvement they anticipated seeing in their mental health.

Those baseline expectations were significantly predictive of how much each participant's mental health actually improved over the study period.^[5]

The expectancy score explained a substantial portion of the variance in outcomes. This is the mechanistic bridge between the observational and controlled results. In naturalistic studies, participants are self-selected people who chose to microdose, almost certainly because they believed it would help; their baseline expectations are correspondingly high, and those expectations drive downstream improvements. In controlled trials, participants know they might be on placebo, which attenuates both expectations and the mood effects those expectations can produce.

This does not make the benefits imaginary. Expectancy is a real psychological mechanism with real neurochemical correlates. Belief in a treatment triggers measurable biological responses. But it does mean that the current evidence cannot cleanly separate what psilocybin's chemistry is doing from what the act of believing psilocybin will help is doing.

The distinction matters both for the full picture of mood data across survey and clinical study types and for the deeper question of how expectancy shapes the entire microdosing experience.

A 2025 medical review on mushrooms, microdosing, and mental illness by Kinderlehrer noted the practical clinical implications of this uncertainty. Distinguishing expectancy from pharmacological effects is not merely an academic concern: it directly affects how practitioners should interpret reported patient improvements and how future trials will need to be designed to separate the two.^[7]

Why Microdosing Might Still Work: The Neuroplasticity Argument

The controlled trial evidence does not prove microdosing has no biological effect on the brain. It proves that in the trials conducted to date, with the sample sizes used, there are no reliably measurable effects on well-being that exceed placebo. Those are different claims, and the distinction matters.

The neurobiological case for why microdosing might produce real antidepressant effects comes from preclinical research. Raval and colleagues, publishing in the International Journal of Molecular Sciences in 2021, gave a single dose of psilocybin to pigs and then measured what happened in their brains. The psilocybin increased the density of synaptic connections, the physical links between neurons, in the prefrontal cortex and other regions. It also decreased the density of serotonin 2A receptors, the primary molecular target for psilocybin.^[6]

This matters for depression theory because depression is associated with reduced synaptic density in prefrontal areas. Treatments that restore synaptic connections, such as ketamine, tend to produce rapid antidepressant effects. If psilocybin, even at sub-perceptual doses, creates new synaptic connections in the brain regions that regulate mood, that would provide a pharmacological explanation for genuine mood benefits that does not require a large or perceptible experience.

The caveat is substantial: this was a single-dose pig study. The translation from pig brain to human depression is uncertain, and Raval used a single dose rather than a repeated microdosing protocol. The neuroplasticity hypothesis is biologically plausible and worth testing in humans. It has not yet been tested in people with depression under controlled conditions.

A 2026 systematic review and meta-analysis by Pinhas and colleagues in Neuroscience and Biobehavioral Reviews provides the most recent quantitative synthesis of the microdosing literature on cognitive function, analyzing effect sizes across controlled and observational studies and documenting the methodological challenges that make clean conclusions difficult.^[8]

For readers interested in the contrast with full-dose psilocybin therapy, where the controlled evidence for depression is substantially stronger, the evidence on whether multiple psilocybin sessions produce lasting depression relief provides the comparison point.

Three Tiers of Evidence: How to Read Conflicting Microdosing Headlines

The apparent contradiction in microdosing research is not evidence of bad science or contradictory data. Thousands of people report it transformed their depression. Two controlled trials found zero effect. These are not incompatible findings. They are what happens when different research methods answer different versions of the same question.

The first tier is anecdotal and survey evidence. Uncontrolled, self-selected, richly detailed. This is where the case for microdosing and depression was built. These reports represent real human experiences. Their limitation is that they cannot distinguish "psilocybin did this" from "believing psilocybin would do this, did this."

The second tier is naturalistic observational studies, of which Rootman 2021 and Rootman 2022 are the strongest examples. These add comparison groups, validated measures, and in Rootman's case a prospective follow-up. They are genuine science for what they are. But participants still know they are microdosing, and self-selected microdosers carry high expectations.

The third tier is placebo-controlled trials. Cavanna 2022 and Szigeti 2021 are the clearest examples currently available. When blinding is maintained and expectancy is modeled, measured effects shrink toward zero. This tier most directly answers the question "does psilocybin have a pharmacological antidepressant effect at microdose levels?" It is also the evidence layer most consistently absent from popular media coverage.

The Ona 2020 systematic review was the first scholarly attempt to articulate this hierarchy: its conclusion that placebo and expectancy are likely driving a meaningful portion of the positive results has been borne out by the subsequent controlled trials.^[9]

Understanding which evidence tier a headline is drawing from tells you how much weight to give it. A survey finding that 70% of microdosers feel less depressed is honest data. A controlled trial finding no benefit versus placebo is also honest data. They are measuring different things, under different conditions, with different amounts of control over the variables that matter most.

For readers who experience depression and are curious how the evidence on psilocybin microdosing for anxiety compares, or what the self-report data shows about microdosing and emotional regulation, those angles are covered in the related articles in this cluster.

The Bottom Line

Survey and observational studies consistently show that people who microdose psilocybin report lower depression scores, with Rootman's 953-person study representing the strongest naturalistic evidence. However, the two placebo-controlled trials conducted to date found no significant well-being benefit once expectancy was statistically controlled, and Kaertner's 2021 study identified positive baseline expectations as the strongest predictor of outcomes. Whether psilocybin produces genuine pharmacological antidepressant effects at microdose levels is an open scientific question that current trial data cannot resolve.

Frequently Asked Questions

Survey and naturalistic studies show people who microdose report lower depression scores, but two placebo-controlled trials found no improvement over placebo once expectations were accounted for. The strongest naturalistic evidence comes from Rootman et al. (2021), which surveyed 953 microdosers and found significantly lower depression scores versus 180 non-microdosing comparators on validated scales. Both Cavanna et al. (2022) in a double-blind trial of 34 participants and Szigeti et al. (2021) in a self-blinding study of 191 participants found that measured benefits disappeared when blinding quality and expectancy were controlled.

The research produces different answers depending on study design. Observational studies with large samples show consistent associations between microdosing and lower depression scores. Controlled trials, specifically Cavanna 2022 (n=34, double-blind) and Szigeti 2021 (n=191, self-blinding), found no significant benefit over placebo. A 2020 systematic review by Ona and colleagues, the first of its kind, concluded that the positive evidence was likely partly driven by expectancy and placebo effects and called for more rigorous controlled trials before conclusions could be drawn.

Expectancy is a powerful and real psychological mechanism. Kaertner and colleagues (2021) measured participants' hopes for microdosing before the study began and found those baseline expectations were the strongest predictor of mental health improvement, stronger than which treatment condition they were assigned to. People who microdose typically expect it to help, and that expectation alone can produce genuine shifts in mood. The experiences people report are real. What is scientifically uncertain is whether psilocybin's pharmacology or the act of believing it will work is the primary driver.

Full-dose psilocybin therapy uses doses high enough to produce a pronounced altered state, typically 20–30mg of pure psilocybin, administered in a clinical setting with trained facilitators. It has a substantially stronger evidence base, including multiple randomized controlled trials showing significant antidepressant effects. Microdosing uses sub-perceptual doses, typically 0.1g–0.5g of dried mushrooms, taken on a repeating schedule without producing a noticeable psychedelic experience. The proposed mechanism differs: full-dose therapy is thought to work through the acute experience itself; microdosing theorizes cumulative neurobiological benefits from repeated low-level serotonin 2A receptor activity. The controlled evidence for full-dose therapy is robust; the controlled evidence for microdosing in depression is null in the trials conducted to date.

Psilocybin is psychoactive even at microdoses, meaning participants often notice subtle effects (a slight perceptual shift, mild energy change) that allow them to guess whether they received the active substance. When participants correctly guess they took psilocybin, their expectations for improvement rise, and those expectations produce real mood improvements. Szigeti's 2021 self-blinding study (n=191) tested this directly: when expectancy and blinding quality were statistically modeled, all improvements in well-being, mindfulness, and convergent thinking disappeared. This makes it structurally difficult to separate a pharmacological effect from a belief-driven one, because the pharmacological effect itself generates clues that alter beliefs.

No completed double-blind placebo-controlled trial has specifically targeted major depressive disorder using a psilocybin microdosing protocol. The two controlled trials that have been conducted, Cavanna et al. (2022) and Szigeti et al. (2021), tested broader outcomes including well-being, mood, and cognitive function rather than clinical depression as a primary endpoint, and both found no significant benefit over placebo once expectancy was controlled. Uncontrolled observational studies show associations between microdosing and lower depression scores, but those designs cannot establish that psilocybin is the cause of the improvement.

Sources & References

1. Source details for this reference are not yet available.
2. Source details for this reference are not yet available.
3. Source details for this reference are not yet available.
4. Source details for this reference are not yet available.
5. Source details for this reference are not yet available.
6. Source details for this reference are not yet available.
7. Source details for this reference are not yet available.
8. Source details for this reference are not yet available.
9. Source details for this reference are not yet available.